Forbes reporter Fiona McMillan writes that MIT researchers have engineered an anti-bacterial peptide found in wasp venom in an effort to create a new antibiotic. McMillan writes that the researchers, “gained new insight into which structural attributes work best, either alone or in combination. In this way, they were able to tweak the peptide’s structure to obtain optimal function.”
MIT researchers have repurposed the toxic venom found in wasps to create a new drug that could potentially be used to kill bacteria, reports the Xinhua news agency. “The venom-derived peptide is believed to kill microbes by disrupting bacterial cell membranes,” Xinhua explains.
Boston Herald reporter Jordan Graham writes that MIT researchers have used the venom from a South American wasp to engineer a new type of antibiotic. “The idea here is to take that very well-crafted toxin and turn it into something that can be useful for humans and our society,” explains César de la Fuente Nunez, a postdoc at MIT.
Prof. Linda Griffith speaks with Hari Sreenivasan of PBS NewsHour about her work developing a new “body on a chip” that could allow researchers to test new drugs on organ tissue. Griffith explains that the device models how different organs and cells communicate in the human body, which is “really important for things like arthritis, Alzheimer's, where you've got multiple organs involved.”
MIT startup Lyndra has found that an ingestible device originally developed by researchers from MIT and Brigham and Women’s Hospital can help tackle the problem of medication adherence, reports Kate Sheridan for STAT. The new technology could make it possible for patients to take “one pill a week for conditions as varied as Alzheimer’s, addiction, allergies, malaria, schizophrenia, high cholesterol, and HIV.”
Prof. Linda Griffith speaks with Wall Street Journal reporter Mark Ellwood about her work developing a new device that allows researchers to test how a drug affects the human body. Ellwood notes that the technology that Griffith and her team have created “could prove vital for rapidly releasing new vaccines.”
A team of researchers led by Prof. J. Christopher Love has developed a system to produce on-demand clinical-grade vaccines and drugs, writes Dr. Francis Collins on the NIH Director’s Blog. In addition to allowing on site production for hospitals the systems could also “produce biologic treatments specially tailored to attack the cancer of a particular individual,” suggests Collins.
Writing for STAT, Karen Weintraub spotlights Prof. J. Christopher Love’s work developing a new desktop drug manufacturing process that can produce thousands of doses of biopharmaceuticals on demand. “I think in the long run there’ll be an opportunity to think about manufacturing for patients in a new way,” says Love.
In an article for Forbes, Charles Towers-Clark spotlights how MIT researchers developed a surgical technique that allows amputees to receive feedback from prosthetic limbs. The technique, Towers-Clark writes, “uses a muscle graft from another part of the body to complete the muscle pair, avoiding rejection which currently occurs in around 20% of cases, and allowing the patient to communicate naturally with the new limb.”
MIT researchers have developed a machine learning system that could reduce the number of chemotherapy and radiotherapy treatments that glioblastoma patients receive, reports the Xinhua News Agency. The system “finds an optimal treatment plan, with the lowest possible potency and frequency of doses that should still reduce tumor sizes,” Xinhua explains.
MIT researchers have developed a new prosthetic device that allows amputees to feel where their limbs are located, reports Simon Makin for Scientific American. “What's new here is the ability to provide feedback the brain knows how to interpret as sensations of position, speed and force,” explains postdoctoral associate Tyler Clites.
MIT researchers have developed a sensor that can determine if cancer cells are responding to a certain chemotherapy drug. “Another potential use is to screen patients before they receive such drugs, to see if the drugs will be successful against each patient's tumor,” writes Li Xia for Xinhua.
In an article for Forbes about how AI could improve healthcare, Bernard Marr highlights an algorithm developed by MIT researchers that can analyze 3-D scans up to 1,000 times faster than is currently possible. “When saving minutes can mean saving lives, AI and machine learning can be transformative,” writes Marr.
Axios reporter Sam Baker highlights a new working paper co-authored by Prof. Jonathan Gruber that provides evidence that doctors do practice “defensive medicine” in an effort to avoid lawsuits. Gruber and his colleague found that, “the threat of malpractice suits raises health care costs by about 5%.”
By using “nanoparticle ‘backpacks’ with immune-stimulating drugs,” MIT researchers were able to enhance T cells and destroy solid tumors without harmful side effects, reports Allen Cone of UPI. "We found you could greatly improve the efficacy of the T cell therapy with backpacked drugs that help the donor T cells survive and function more effectively,"explains Prof. Darrell Irvine.